Lipocine announces presentation at 2022 epilepsy foundation pipeline conference

Salt lake city , june 6, 2022 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented "lpcn 2101: an endogenous neuroactive steroid for epilepsy" today at the 2022 epilepsy foundation pipeline conference.  the conference is held every two years to bring together decision-makers in the field of epilepsy treatment, therapeutic innovation and development, showcasing the latest developments in the epilepsy pipeline.
LPCN Ratings Summary
LPCN Quant Ranking